News Resistance grows to Recordati's private equity takeover The offer for Recordati by private equity firms CVC and GBL undervalues the company and is unfair to minority shareholders, claims activist investor.
News Acquisitive Lilly offers $2.88bn for Merida Bio Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.
News BioMarin snaps up Alesta's lead asset for $275m BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.
News After failure in sickle cell, Fulcrum merges with Slate Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
News Sanofi to lay off 229 Blueprint employees, close offices A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.
News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.